Canlyniadau Chwilio - Laurence Albigès

Mireinio'r Canlyniadau
  1. 1
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential gan Camille Mazza, Bernard Escudier, Laurence Albigès

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma gan Elie Rassy, Ronan Flippot, Laurence Albigès

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer gan Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma gan Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases gan Laurence Albigès, Fabrice André, Corinne Balleyguier, Gonzalo Gomez-Abuin, Agnès Chompret, Suzette Delaloge

    Cyhoeddwyd 2005
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma gan Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma gan Laurence Albigès, Foucauld Chamming’s, Brigitte Duclos, M. Stern, Robert J. Motzer, Alain Ravaud, P. Camus

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography gan Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma gan Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurélien Marabelle, Laurence Albigès, Angélo Paci

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events gan Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients gan Luc Cabel, Elika Loir, Gwénaëlle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albigès, Giulia Baciarello, Yohann Loriot, Karim Fizazi

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma gan Guillermo de Velasco, Katherine M. Krajewski, Laurence Albigès, Mark M. Awad, Joaquim Bellmunt, F. Stephen Hodi, Toni K. Choueiri

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma gan Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Who dies from prostate cancer?

    Who dies from prostate cancer? gan Anna Patrikidou, Yohann Loriot, J-C Eymard, Laurence Albigès, Christophe Massard, E. Ileana, Mario Di Palma, Bernard Escudier, Karim Fizazi

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Renal cell carcinoma

    Renal cell carcinoma gan James J. Hsieh, Mark P. Purdue, Sabina Signoretti, Charles Swanton, Laurence Albigès, Manuela Schmidinger, Daniel Y.C. Heng, James Larkin, Vincenzo Ficarra

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) gan Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience gan Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma gan Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Chk1 as a new therapeutic target in triple-negative breast cancer

    Chk1 as a new therapeutic target in triple-negative breast cancer gan Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors gan Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: